Definitive Healthcare (DH)

• Market cap: $289M
• 1 day: -6.91%
• 5 days: -2.66%
• 1 month: -52.94%
• 3 months: -42.98%
• 6 months: -42.34%
• Year to date: -37.86%
• 1 year: -68.74%
• 5 years: -94.09%
• 10 years: -94.09%
• Sector: Information Technology
• Industry: Prepackaged Software

About: Definitive Healthcare Corp is a provider of healthcare commercial intelligence. Its SaaS-based healthcare commercial intelligence platform is designed to provide comprehensive and accurate information on the healthcare ecosystem in the U.S. The platform uses deep analytics and data science to help customers develop data-driven strategic decisions, such as finding new markets to enter, building comprehensive go-to-market strategies, accessing tactical information to help target the right decision makers, and improving win rates with detailed contextual information. The company derives substantially all of its revenue from the sale of subscription fees for access to its platform and stand-ready support. Geographically, it derives a majority of its revenue from the United States.

Employees: 782

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

688% more call options, than puts

Call options by funds: $134K | Put options by funds: $17K

35% more repeat investments, than reductions

Existing positions increased: 50 | Existing positions reduced: 37

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

2% more funds holding

Funds holding: 125 [Q3] → 128 (+3) [Q4]

0.08% more ownership

Funds ownership: 90.81% [Q3] → 90.9% (+0.08%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]

9% less capital invested

Capital invested by funds: $475M [Q3] → $432M (-$43.9M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $3 17% upside
• Avg. target: $3.67 43% upside
• High target: $5 95% upside

3 analyst ratings

• positive: 0 0%
• neutral: 2 67%
• negative: 1 33%

Goldman Sachs Kash Rangan 37% 1-year accuracy 10 / 27 met price target	17% upside $3	Neutral Maintained	4 Mar 2025
Barclays Saket Kalia 40% 1-year accuracy 21 / 52 met price target	17% upside $3	Underweight Maintained	3 Mar 2025
Stephens & Co. Jeff Garro 42% 1-year accuracy 5 / 12 met price target	95% upside $5	Equal-Weight Initiated	20 Dec 2024